- Home
- TPST vs IGC Comparison
TPST vs IGC Comparison
Compare TPST & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- IGC
- Stock Information
- Founded
- TPST 2011
- IGC 2005
- Country
- TPST United States
- IGC United States
- Employees
- TPST N/A
- IGC N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- TPST Health Care
- IGC Health Care
- Exchange
- TPST Nasdaq
- IGC Nasdaq
- Market Cap
- TPST 27.2M
- IGC 26.9M
- IPO Year
- TPST N/A
- IGC N/A
- Fundamental
- Price
- TPST $0.70
- IGC $0.38
- Analyst Decision
- TPST Strong Buy
- IGC Strong Buy
- Analyst Count
- TPST 4
- IGC 2
- Target Price
- TPST $20.00
- IGC $3.75
- AVG Volume (30 Days)
- TPST 1.4M
- IGC 465.1K
- Earning Date
- TPST 11-12-2024
- IGC 02-12-2025
- Dividend Yield
- TPST N/A
- IGC N/A
- EPS Growth
- TPST N/A
- IGC N/A
- EPS
- TPST N/A
- IGC N/A
- Revenue
- TPST N/A
- IGC $1,183,000.00
- Revenue This Year
- TPST N/A
- IGC N/A
- Revenue Next Year
- TPST N/A
- IGC $13.57
- P/E Ratio
- TPST N/A
- IGC N/A
- Revenue Growth
- TPST N/A
- IGC N/A
- 52 Week Low
- TPST $0.70
- IGC $0.25
- 52 Week High
- TPST $6.00
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- TPST 24.08
- IGC 50.02
- Support Level
- TPST $0.86
- IGC $0.35
- Resistance Level
- TPST $0.86
- IGC $0.40
- Average True Range (ATR)
- TPST 0.07
- IGC 0.03
- MACD
- TPST -0.01
- IGC 0.00
- Stochastic Oscillator
- TPST 0.00
- IGC 32.71
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.